Osteoarthritis (OA) is one of the most common joint diseases that is considered a chronic degenerative disorder. There is no effective therapy available today. This prospective clinical trial is designed in an attempt to study the efficacy of mesenchymal stem cells with platelet rich plasma in knee osteoarthritis.

Inclusion Criteria:

• 30-70 years old.
• No serious infection, chronic diseases, diabetes and tuberculosis.
• Osteoarthritis of the knee with grade1-3 defined by the modified Kellgren-Lawrence classification.
• Written informed consents were obtained from all subjects.

Exclusion Criteria:

• Pregnant women or cognitively impaired adults.
• Inflammatory or post infectious arthritis.
• Intra-articular drug injection within the previous 2 months.
• Serious medical illness with a life expectancy of less than 1 year.
• Prior admission for substance abuse.
• Arthroscopy during the previous 6 months.
• Systemic autoimmune rheumatic disease.
• Poorly controlled diabetes mellitus.
• Immunosuppressive or anticoagulant treatments.
• Treatment with corticosteroids in the 3 months prior to inclusion in the study.
• NSAID therapy within 15 days prior to inclusion in the study.